Folate-fluorescein isothiocyanate (folate-FITC)

Drug Overview

The medication known as folate-FITC (also referred to as EC17) is a highly specialized medical tool used in the field of oncology. It is not a traditional medicine used to kill cancer cells or cure disease. Instead, it is an advanced “Smart Diagnostic” agent. Doctors use it as a molecular “scout” to help identify specific types of cancer cells and to help the immune system recognize them.

Folate-FITC acts like a fluorescent beacon. By attaching a glowing marker to a vitamin that cancer cells “crave,” this agent makes the cancer cells visible to special medical equipment and can help guide targeted treatments.

Here are the key details about this agent:

• Generic Name: Folate-fluorescein isothiocyanate (folate-FITC).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Diagnostic Imaging Agent / Targeted Immunotherapy Sensitizer.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is being studied in advanced clinical trials, particularly for ovarian and lung cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand folate-FITC, it helps to imagine a cancer cell as a hungry traveler looking for food. Cancer cells grow very fast, and to do that, they need a lot of a vitamin called folate (vitamin B9).

The Homing Device (Folate)

Most aggressive cancer cells have an unusually high number of “entry doors” on their surface called Folate Receptor Alpha (FRa). Healthy cells have very few of these doors. Folate-FITC is designed to seek out these specific receptors.

The Molecular Beacon (FITC)

The “FITC” part of the name stands for fluorescein isothiocyanate. This is a bright green fluorescent dye. When this dye is attached to the folate, the entire molecule travels through the blood until it finds a cancer cell with an FRa “door.”

How It Works at the Molecular Level:

1. Targeted Binding: Once folate-FITC is injected, it travels through the body. The folate part of the molecule acts as a key that fits into the FRa receptor “lock” on the cancer cell surface.
2. Internalization: The cancer cell “swallows” the folate-FITC molecule, thinking it is just getting its regular vitamin supply.
3. Trapping and Imaging: The fluorescent dye becomes trapped inside or on the surface of the tumor.
4. Sensitization: In some treatments, folate-FITC is used with special antibodies. The FITC dye acts as a target. Once the cancer cell is “painted” with the green dye, the body’s immune system or specially designed drugs can find and destroy the “painted” cells while leaving healthy, “unpainted” cells alone.

FDA Approved Clinical Indications

Because folate-FITC is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Ovarian Cancer: Used to identify tumors that overexpress folate receptors to guide surgical removal.
• Non-Small Cell Lung Cancer (NSCLC): Used to help visualize the margins of a tumor during surgery.
• Renal Cell Carcinoma (Kidney Cancer): Used to detect small clusters of cancer cells that might be missed by standard scans.
• Targeted Immunotherapy: Used in combination with “anti-FITC” antibodies to create a bridge between the cancer cell and the immune system.

Non-oncological Uses:

• There are currently no non-oncological uses for this agent.

Dosage and Administration Protocols

Because folate-FITC is used for imaging or as a “pre-treatment” for immunotherapy, it is not taken as a daily pill. It is usually given as a single dose shortly before a procedure.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) highlight the powerful role folate-FITC plays in “Precision Oncology.”

• Surgical Precision: In trials for ovarian cancer, surgeons using folate-FITC were able to find additional cancerous lesions in roughly 25 percent of patients that were not visible to the naked eye or found by touch.
• Improving Survival Rates: While folate-FITC is a diagnostic tool, its use helps improve survival by ensuring more of the tumor is removed during surgery. Research suggests that “complete resection” (removing all visible cancer) is the strongest predictor of long-term survival in these patients.
• Immune Targeting: Early data from immunotherapy trials shows that “painting” tumors with folate-FITC allows anti-FITC drugs to reach the tumor with high accuracy, reducing the “off-target” damage to healthy organs.

Safety Profile and Side Effects

Because folate-FITC is used in very small amounts for imaging, it does not cause the severe side effects associated with standard chemotherapy like hair loss or extreme nausea.

Common Side Effects (greater than 10 percent):

• Injection Site Reactions: Mild pain, redness, or bruising where the IV was placed.
• Nausea: A small number of patients feel slight stomach upset shortly after the infusion.
• Taste Changes: Some patients report a metallic or unusual taste in the mouth during the injection.

Serious Adverse Events:

• Allergic Reactions (Rare): As with any IV medication, there is a very small risk of an allergic reaction (anaphylaxis), which can cause hives, swelling of the face, or low blood pressure.
• Photosensitivity: Because the drug uses a fluorescent dye, your skin and eyes may be slightly more sensitive to bright light for 24 hours.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• For Nausea: Standard anti-nausea medicine can be given if needed, but the feeling usually passes quickly.
• Allergy Management: The medical team monitors your heart rate and breathing during the infusion to catch any reactions early.
• Light Protection: Patients are often advised to wear sunglasses and avoid direct sunlight for several hours after receiving the drug.

Research Areas

Folate-FITC is a major focus in Immunotherapy and Regenerative Medicine research.

Scientists are currently looking at how folate-FITC can be used with CAR-T cell therapy. By “painting” a tumor with folate-FITC, they can train T-cells (the body’s “soldier” cells) to specifically attack the green-glowing cells. This is a very targeted form of therapy that could change how we treat resistant cancers.

In the field of regenerative medicine, researchers are exploring if folate receptors can be used to identify healthy, growing stem cells versus abnormal ones, ensuring that only the healthiest cells are used in tissue repair.

Patient Management and Practical Recommendations

To ensure the best scan or surgical results, patients should follow specific guidelines.

Pre-treatment Tests to be Performed:

• Folate Receptor Testing: A biopsy may be tested to ensure the tumor has the “entry doors” (FRa) that the drug needs to work.
• Pregnancy Test: A negative pregnancy test is strictly required for women of childbearing age, as the effect of the dye on an unborn baby is not fully known.

Precautions During Treatment:

• Avoid Folate Supplements: You may be asked to stop taking folic acid vitamins for 48 hours before the procedure. If you have too much folate in your system, it can “block the doors,” and the folate-FITC won’t be able to get inside the cancer cells.
• Skin Protection: Bring a hat and sunglasses to your appointment in case you feel sensitive to the light afterward.

“Do’s and Don’ts” List:

• DO drink plenty of water to help your kidneys flush the tracer out after the procedure.
• DO tell your doctor if you have ever had an allergy to fluorescent dyes used in eye exams.
• DON’T take multivitamins or “prenatal” vitamins the day of your procedure unless your doctor says it is okay.
• DON’T worry if your urine looks slightly different in color for a day; this is just the dye leaving your body.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Folate-FITC is an investigational diagnostic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.